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Fecal microbiota transplantation (FMT) is effective for recurrent Clostridium difficile infection (CDI) [1] . There is concern that systemic antibiotic use within the first 8 weeks after FMT may disrupt engraftment of the recently transferred donor's microbiota and therefore may limit FMT effectiveness [2] . Data from a large clinical trial using monoclonal antitoxin antibody (bezlotoxumab) suggests that systemic non-CDI antibiotics use is common (35%) among CDI patients within 8 weeks of receiving standard-of-care therapy [3] . In a large cohort study evaluating predictors of FMT failure, severe CDI, inpatient status, and number of prior CDI episodes were found to significantly increase the odds of treatment failure; however, the authors did not examine the impact of early systemic antibiotic use [4] . Accordingly, we aimed to assess the burden of early antibiotic use among patients who had undergone FMT within the past 8 weeks and the impact of early antibiotic use on FMT failure.
METHODS
We performed a retrospective study at 2 academic FMT referral centers. Consecutive patients between May 2012 and September 2016 who underwent FMT for recurrent CDI were included. Recurrent CDI was defined as at least 3 confirmed episodes of CDI by either polymerase chain reaction (PCR) or enzyme immunoassay (EIA) toxin testing and failure to achieve cure after standard antibiotic therapy. FMT was delivered via the lower gastrointestinal tract with either flexible sigmoidoscopy or colonoscopy at the discretion of the endoscopist or capsule. Both patient-directed and universal stool donors were used, which included both fresh or frozen donor material, depending on availability [5] . Post-FMT follow-up included either clinic visits or phone calls over the 8-week post-FMT follow-up period to assess for diarrheal symptoms that are concerning for failure. 
RESULTS
We identified 349 patients who underwent FMT for recurrent CDI. The mean age was 62.8 years ± 19.2, and there was a preponderance of females (64.8%; n = 226/349). Among the cohort, the FMT failure rate was 12.6% (n = 44/349). Overall, 29 patients received non-CDI antibiotics within 8 weeks of the FMT (8.3%). Among the patients who received non-CDI antibiotics, 14 patients developed diarrhea, of which 8 patients had positive laboratory test confirming CDI by either PCR or EIA. The median days of non-CDI antimicrobials received was 7 for both FMT failures and nonfailures. Therefore, the overall FMT failure rate was 27.6% (n = 8/29) among patients who received early antibiotics after FMT. Patients who experienced FMT failure were offered repeat FMT or anti-CDI antibiotics at the discretion of the treating physician. Exposure to antibiotics within 8 weeks of FMT significantly increased the risk of CDI recurrence compared with nonexposure (27.6% vs 11.3%; P = .01). Logistic regression was performed to assess whether early antibiotic use was a risk factor for FMT failure after adjusting for age, sex, and severity of CDI. After adjustment for prognostically important variables, early antibiotic exposure still carried an almost 3-fold increase in risk of failure (odds ratio, 2.86; 95% confidence interval, 1.16-7.06; P = .02). Most patients received antibiotics within 4 weeks of FMT (70.5%). The most common reasons for antibiotic use were urinary tract infection (36%), pneumonia/upper respiratory tract infection (20%), and cellulitis or skin/soft tissue infection (12%). The most common antibiotics prescribed were ciprofloxacin (30%), cephalexin (20%), and amoxicillin or amoxicillin-clavulanic acid (12%).
CONCLUSION
Early antibiotic exposure among CDI patients who have undergone a recent FMT is not uncommon within 8 weeks of FMT.
Antibiotic use during what is felt to be a vulnerable period for the microbiome does seem to result in a markedly increased risk of FMT failure. Even after adjustment for other known risk factors, early antibiotic exposure was the strongest predictor of FMT failure in our model. Clinicians should be thoughtful about antibiotic use and optimize antibiotic stewardship practices in the immediate post-FMT period. Appropriate diagnostics should be used, and narrow-spectrum antibiotics should be used when appropriate, preferably in consultation with an FMT/infectious disease specialist. 
